Skip to NavigationSkip to content

News

It was found that the combo reduced time taken to achieve recovery in patients hospitalised with COVID-19 compared to remdesivir alone, with an...
The deal sees MSD gain access to Seattle Genetics’ LIV-1 inhibitor iadiratuzumab vedotin and tyrosine kinase inhibitor Tuksya.
Shionogi has announced the launch of its new antibiotic in the UK for the treatment of infections due to aerobic Gram-negative bacteria in patients...
Sir Patrick Vallance, the Chief Scientific Adviser to the UK Government, was “told off” for advocating for an early lockdown to stop the spread of...
Biopharma and pharmaceutical companies developing treatments and vaccines have long faced operational challenges that cost time and money while...
Following investigation from independent committees and international regulators of generated safety data, the trial programme has now received the...
The primary focus of the deal for Gilead is Immunomedics’ Trop-2 directed antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy), which it...
This was driven primarily by infections in the US, Brazil and India, and totalled 307,930 new cases over 24 hours. India had 94,372 cases on Sunday,...
Speaking to “Face the Nation” on CBS, CEO Albert Bourla said the company will be ready to manufacture hundreds of thousands of doses in preparation...
President Trump has signed an executive order that could cut drug prices by tying them to similar prices in countries with socialised healthcare...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches